Product Description
Mechanisms of Action: PDK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | India | Peru | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: University of Florida
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Insulin Resistance
Phase 3: Pyruvate Dehydrogenase Complex Deficiency Disease|Acidosis, Lactic
Phase 2: MELAS Syndrome|Glioblastoma|Head and Neck Cancer|Acidosis, Lactic|Non-Small-Cell Lung Cancer|Breast Cancer|Squamous Cell Carcinoma|Multiple Myeloma|Glioma|Healthy Volunteers
Phase 1: Lung Cancer|Potassium Deficiency|Evans Syndrome|MELAS Syndrome|Protein Deficiency|Hypertension, Pulmonary|Liver Cancer|Brain Cancer|Familial Primary Pulmonary Hypertension|Acidosis, Lactic|Breast Cancer|Tumor Lysis Syndrome|Brain Death|Glioblastoma|Healthy Volunteers|Brain Injuries|Pyruvate Dehydrogenase Complex Deficiency Disease|Deficiency Diseases|Head and Neck Cancer|Hyperglycemia|Mitochondrial Diseases|Hypoglycemia|Type 1 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
HSC-MS-24-0756 | N/A |
Not yet recruiting |
Generalized anxiety disorder |
2027-06-30 |
|
DCA | P2 |
Not yet recruiting |
Glioblastoma |
2026-12-30 |
|
ACTRN12623001164684 | N/A |
Recruiting |
Anal Cancer|Nose Cancer |
2026-10-30 |
|
NCT05317455 | P1 |
Not yet recruiting |
Hypoglycemia|Type 1 Diabetes |
2025-10-01 |